.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Merck
Accenture
Express Scripts
Cerilliant
Novartis
AstraZeneca
Argus Health
Fuji
Mallinckrodt

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,233,115

« Back to Dashboard

Which drugs does patent 9,233,115 protect, and when does it expire?


Patent 9,233,115 protects NINLARO and is included in one NDA.

This patent has thirty-four patent family members in twenty-nine countries.

Summary for Patent: 9,233,115

Title:Proteasome inhibitors and methods of using the same
Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.
Inventor(s): Bernardini; Raffaella (Calci, IT), Bernareggi; Alberto (Concorezzo, IT), Cassara; Paolo G. (Monza, IT), Chatterjee; Sankar (Wynnewood, PA), D'Arasmo; Germano (Novate Milanese, IT), De Munari; Sergio (Milan, IT), Ferretti; Edmondo (Ravenna, IT), Iqbal; Mohamed (Malvern, PA), Menta; Ernesto (Cemusco sul Naviglio, IT), Messina McLaughlin; Patricia A. (Glen Mills, PA), Oliva; Ambrogio (Saronno, IT)
Assignee: Millennium Pharmaceuticals Inc. (Cambridge, MA)
Application Number:13/949,346
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Millennium PharmsNINLAROixazomib citrateCAPSULE;ORAL208462-001Nov 20, 2015RXYesNo► Subscribe► SubscribeMETHOD FOR TREATING MULTIPLE MYELOMA► Subscribe
Millennium PharmsNINLAROixazomib citrateCAPSULE;ORAL208462-002Nov 20, 2015RXYesNo► Subscribe► SubscribeMETHOD FOR TREATING MULTIPLE MYELOMA► Subscribe
Millennium PharmsNINLAROixazomib citrateCAPSULE;ORAL208462-003Nov 20, 2015RXYesYes► Subscribe► SubscribeMETHOD FOR TREATING MULTIPLE MYELOMA► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,233,115

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,576,206Proteasome inhibitors and methods of using the same► Subscribe
8,546,608Proteasome inhibitors and methods of using the same► Subscribe
8,058,262Proteasome inhibitors and methods of using the same► Subscribe
7,915,236Proteasome inhibitors and methods of using the same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,233,115

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
MexicoPA06001687► Subscribe
European Patent Office1660507► Subscribe
Spain2330008► Subscribe
Hong Kong1091839► Subscribe
CroatiaP20090590► Subscribe
Israel173722► Subscribe
Israel217623► Subscribe
Iceland8343► Subscribe
Japan2007502304► Subscribe
Japan4917431► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Julphar
Johnson and Johnson
AstraZeneca
Colorcon
US Army
Citi
UBS
Fish and Richardson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot